TY - JOUR
T1 - CD4+ and CD8+ cytotoxic T lymphocytes may induce mesenchymal cell apoptosis in IgG4-related disease
AU - Perugino, Cory A.
AU - Kaneko, Naoki
AU - Maehara, Takashi
AU - Mattoo, Hamid
AU - Kers, Jesper
AU - Allard-Chamard, Hugues
AU - Mahajan, Vinay S.
AU - Liu, Hang
AU - Della-Torre, Emanuel
AU - Murphy, Samuel J.H.
AU - Ghebremichael, Musie
AU - Wallace, Zachary S.
AU - Bolster, Marcy B.
AU - Harvey, Liam M.
AU - Mylvaganam, Geetha
AU - Tuncay, Yesim
AU - Liang, Lloyd
AU - Montesi, Sydney B.
AU - Zhang, Xiuwei
AU - Tinju, Akira
AU - Mochizuki, Keita
AU - Munemura, Ryusuke
AU - Sakamoto, Mizuki
AU - Moriyama, Masafumi
AU - Nakamura, Seiji
AU - Yosef, Nir
AU - Stone, John H.
AU - Pillai, Shiv
N1 - Funding Information:
This work was supported by the National Institutes of Health (NIH) Autoimmune Centers of Excellence (grant no. U19 AI 110495 to S.P.). C.A.P. was supported by a Rheumatology Research Foundation Scientist Development Award, a Scleroderma Foundation New Investigator Grant and a Sponsored Research Agreement with UCB. T.M. was supported by Japan Society for the Promotioin of Science (grant no. JP18KK0260 ) and the Takeda Science Foundation . J.K. was supported by a Work Visit Grant of the Amsterdam Infection and Immunity Institute . V.S.M. was supported by the NIH (grant no. AI113163 ). M.G. was supported by the National Institute of Allergy and Infectious Diseases (grant no. P30AI060354 ). E.D.-T. was supported by the Giovani Ricercatori Research Grant from the Cariplo Foundation . S.B.M. was supported by a Parker B. Francis Fellowship and a Scleroderma Foundation New Investigator Grant, and J.H.S. was supported by the NIH Autoimmune Centers of Excellence (grant no. UM1 AI1144295 ).
Funding Information:
This work was supported by the National Institutes of Health (NIH) Autoimmune Centers of Excellence (grant no. U19 AI 110495 to S.P.). C.A.P. was supported by a Rheumatology Research Foundation Scientist Development Award, a Scleroderma Foundation New Investigator Grant and a Sponsored Research Agreement with UCB. T.M. was supported by Japan Society for the Promotioin of Science (grant no. JP18KK0260) and the Takeda Science Foundation. J.K. was supported by a Work Visit Grant of the Amsterdam Infection and Immunity Institute. V.S.M. was supported by the NIH (grant no. AI113163). M.G. was supported by the National Institute of Allergy and Infectious Diseases (grant no. P30AI060354). E.D.-T. was supported by the Giovani Ricercatori Research Grant from the Cariplo Foundation. S.B.M. was supported by a Parker B. Francis Fellowship and a Scleroderma Foundation New Investigator Grant, and J.H.S. was supported by the NIH Autoimmune Centers of Excellence (grant no. UM1 AI1144295).
Publisher Copyright:
© 2020 American Academy of Allergy, Asthma & Immunology
PY - 2021/1
Y1 - 2021/1
N2 - Background: IgG4-related disease (IgG4-RD) is an immune-mediated fibrotic disorder that has been linked to CD4+ cytotoxic T lymphocytes (CD4+CTLs). The effector phenotype of CD4+CTLs and the relevance of both CD8+ cytotoxic T lymphocytes (CD8+CTLs) and apoptotic cell death remain undefined in IgG4-RD. Objective: We sought to define CD4+CTL heterogeneity, characterize the CD8+CTL response in the blood and in lesions, and determine whether enhanced apoptosis may contribute to the pathogenesis of IgG4-RD. Methods: Blood analyses were undertaken using flow cytometry, cell sorting, transcriptomic analyses at the population and single-cell levels, and next-generation sequencing for the TCR repertoire. Tissues were interrogated using multicolor immunofluorescence. Results were correlated with clinical data. Results: We establish that among circulating CD4+CTLs in IgG4-RD, CD27loCD28loCD57hi cells are the dominant effector subset, exhibit marked clonal expansion, and differentially express genes relevant to cytotoxicity, activation, and enhanced metabolism. We also observed prominent infiltration of granzyme A–expressing CD8+CTLs in disease tissues and clonal expansion in the blood of effector/memory CD8+ T cells with an activated and cytotoxic phenotype. Tissue studies revealed an abundance of cells undergoing apoptotic cell death disproportionately involving nonimmune, nonendothelial cells of mesenchymal origin. Apoptotic cells showed significant upregulation of HLA-DR. Conclusions: CD4+CTLs and CD8+CTLs may induce apoptotic cell death in tissues of patients with IgG4-RD with preferential targeting of nonendothelial, nonimmune cells of mesenchymal origin.
AB - Background: IgG4-related disease (IgG4-RD) is an immune-mediated fibrotic disorder that has been linked to CD4+ cytotoxic T lymphocytes (CD4+CTLs). The effector phenotype of CD4+CTLs and the relevance of both CD8+ cytotoxic T lymphocytes (CD8+CTLs) and apoptotic cell death remain undefined in IgG4-RD. Objective: We sought to define CD4+CTL heterogeneity, characterize the CD8+CTL response in the blood and in lesions, and determine whether enhanced apoptosis may contribute to the pathogenesis of IgG4-RD. Methods: Blood analyses were undertaken using flow cytometry, cell sorting, transcriptomic analyses at the population and single-cell levels, and next-generation sequencing for the TCR repertoire. Tissues were interrogated using multicolor immunofluorescence. Results were correlated with clinical data. Results: We establish that among circulating CD4+CTLs in IgG4-RD, CD27loCD28loCD57hi cells are the dominant effector subset, exhibit marked clonal expansion, and differentially express genes relevant to cytotoxicity, activation, and enhanced metabolism. We also observed prominent infiltration of granzyme A–expressing CD8+CTLs in disease tissues and clonal expansion in the blood of effector/memory CD8+ T cells with an activated and cytotoxic phenotype. Tissue studies revealed an abundance of cells undergoing apoptotic cell death disproportionately involving nonimmune, nonendothelial cells of mesenchymal origin. Apoptotic cells showed significant upregulation of HLA-DR. Conclusions: CD4+CTLs and CD8+CTLs may induce apoptotic cell death in tissues of patients with IgG4-RD with preferential targeting of nonendothelial, nonimmune cells of mesenchymal origin.
UR - http://www.scopus.com/inward/record.url?scp=85087749791&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087749791&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2020.05.022
DO - 10.1016/j.jaci.2020.05.022
M3 - Article
C2 - 32485263
AN - SCOPUS:85087749791
SN - 0091-6749
VL - 147
SP - 368
EP - 382
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 1
ER -